Search

Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2016

Protocol T 2-Year Data

Neil Bressler, MD, Tim Murray, MD

Show Description +

Tim Murray, MD, MBA, sits down with Tim Murray, MD, MBA, to talk about new findings from the DRCR.net Protocol T study. The 1-year results from this clinical trial showed that patients with 20/50 or worse baseline visual acuity who received aflibercept gained more letters than patients who received ranibizumab or bevacizumab. Drs. Murray and Bressler discuss the recently released 2-year study results, and whether aflibercept is still the best option for patients with poor visual acuity at baseline.

Posted: 3/07/2016

Keywords:

Protocol T 2-Year Data

Up Next

Acute Ocriplasmin Retinopathy

Acute Ocriplasmin Retinopathy

Mark Johnson, MD, Tim Murray, MD

Treatments Using Gene Therapy and Engineered Cells

Treatments Using Gene Therapy and Engineered Cells

Szilard Kiss, MD, Tim Murray, MD

Advances in Pediatric Vitreoretinal Surgery

Advances in Pediatric Vitreoretinal Surgery

R.V. Paul Chan, MD, Tim Murray, MD

VMT Management: Watch and Wait

VMT Management: Watch and Wait

Harry W. Flynn Jr., MD, Tim Murray, MD

Imaging and Uveitis: How to Apply Imaging Information

Imaging and Uveitis: How to Apply Imaging Information

Glenn Jaffe, MD, Tim Murray, MD

Macular Hole Repair in the Small-Gauge Era

Macular Hole Repair in the Small-Gauge Era

Tarek Hassan, MD, Tim Murray, MD

Update on Health Care Policy

Update on Health Care Policy

David W. Parke II, MD, Tim Murray, MD

Back to All Videos

Protocol T 2-Year Data

Neil Bressler, MD, Tim Murray, MD

Tim Murray, MD, MBA, sits down with Tim Murray, MD, MBA, to talk about new findings from the DRCR.net Protocol T study. The 1-year results from this clinical trial showed that patients with 20/50 or worse baseline visual acuity who received aflibercept gained more letters than patients who received ranibizumab or bevacizumab. Drs. Murray and Bressler discuss the recently released 2-year study results, and whether aflibercept is still the best option for patients with poor visual acuity at baseline.

Posted: 3/07/2016

Keywords:

Protocol T 2-Year Data

Please log in to leave a comment.

More From ARDS: 2016 Coverage

VMT Management: Watch and Wait

VMT Management: Watch and Wait

Harry W. Flynn Jr., MD, Tim Murray, MD

Imaging and Uveitis: How to Apply Imaging Information

Imaging and Uveitis: How to Apply Imaging Information

Glenn Jaffe, MD, Tim Murray, MD

Macular Hole Repair in the Small-Gauge Era

Macular Hole Repair in the Small-Gauge Era

Tarek Hassan, MD, Tim Murray, MD

Update on Health Care Policy

Update on Health Care Policy

David W. Parke II, MD, Tim Murray, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARDS: 2016.